Arbutus Biopharma Corporation
ABUS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -95.1% | 508.8% | 12.1% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 97.9% | 100% | -407.9% | -459.7% |
| EBITDA | -$0 | $0 | -$0 | -$0 |
| % Margin | -1,457.1% | 23.9% | -1,369.9% | -974.3% |
| Net Income | -$0 | $0 | -$0 | -$0 |
| % Margin | -1,463.5% | 23.5% | -1,390.4% | -796.2% |
| EPS Diluted | -0.04 | 0.013 | -0.13 | -0.068 |
| % Growth | -405.3% | 110.1% | -92.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |